This is a two-stage trial consisting of a Part I, dose escalation and dose-finding component
to establish the Maximal Tolerated Dose (MTD), if any, and Recommended Part 2 Dose (RP2D) of
XON7, followed by a Part II component to investigate anti-tumors efficacy in selected solid
tumor types and to further evaluate safety and tolerability of XON7 at RP2D.